These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27311868)

  • 21. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cytosolic Ezh1 isoform modulates a PRC2-Ezh1 epigenetic adaptive response in postmitotic cells.
    Bodega B; Marasca F; Ranzani V; Cherubini A; Della Valle F; Neguembor MV; Wassef M; Zippo A; Lanzuolo C; Pagani M; Orlando V
    Nat Struct Mol Biol; 2017 May; 24(5):444-452. PubMed ID: 28346433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2 is a sensitive marker of malignancy in salivary gland tumors.
    Hajósi-Kalcakosz S; Vincze E; Dezső K; Paku S; Rókusz A; Sápi Z; Tóth E; Nagy P
    Diagn Pathol; 2015 Sep; 10():163. PubMed ID: 26377323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration.
    Bae WK; Kang K; Yu JH; Yoo KH; Factor VM; Kaji K; Matter M; Thorgeirsson S; Hennighausen L
    FASEB J; 2015 May; 29(5):1653-62. PubMed ID: 25477280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Divergent Requirements for EZH1 in Heart Development Versus Regeneration.
    Ai S; Yu X; Li Y; Peng Y; Li C; Yue Y; Tao G; Li C; Pu WT; He A
    Circ Res; 2017 Jul; 121(2):106-112. PubMed ID: 28512107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
    Cho YJ; Kim SH; Kim EK; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Jung ST; Kim HS
    BMC Cancer; 2018 Feb; 18(1):158. PubMed ID: 29415665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
    Yamagishi M
    Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
    Choi JH; Song YS; Yoon JS; Song KW; Lee YY
    APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
    Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
    J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
    Rabello Ddo A; Lucena-Araujo AR; Alves-Silva JC; da Eira VB; de Vasconcellos MC; de Oliveira FM; Rego EM; Saldanha-Araujo F; Pittella Silva F
    Blood Cells Mol Dis; 2015 Jan; 54(1):97-102. PubMed ID: 25131810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.
    Wan L; Li X; Shen H; Bai X
    Clin Transl Oncol; 2013 Feb; 15(2):132-8. PubMed ID: 22855181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
    Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
    Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
    D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
    J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.